Here, we synthesized a series of cyclopropylamine-based LSD1 inhibitors and found that these compounds possess potent and selective activity against MLL-rearranged leukemia, with their antileukemia activities correlated with LSD1 inhibitory activity. The gene discussed is KMT2A; the disease is leukemia.